GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Applied BioCode Corp (TPE:6598) » Definitions » EBIT

Applied BioCode (TPE:6598) EBIT : NT$-259.4 Mil (TTM As of Dec. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Applied BioCode EBIT?

Applied BioCode's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2024 was NT$-70.6 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2024 was NT$-259.4 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Applied BioCode's annualized ROC % for the quarter that ended in Dec. 2024 was -96.34%. Applied BioCode's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was -115.37%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Applied BioCode's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was -18.83%.


Applied BioCode EBIT Historical Data

The historical data trend for Applied BioCode's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Applied BioCode EBIT Chart

Applied BioCode Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -99.16 -162.31 -181.93 -161.28 -259.35

Applied BioCode Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8.09 -62.69 -49.60 -76.49 -70.57

Competitive Comparison of Applied BioCode's EBIT

For the Medical Devices subindustry, Applied BioCode's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Applied BioCode's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Applied BioCode's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Applied BioCode's EV-to-EBIT falls into.


;
;

Applied BioCode EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-259.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Applied BioCode  (TPE:6598) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Applied BioCode's annualized ROC % for the quarter that ended in Dec. 2024 is calculated as:

ROC % (Q: Dec. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2024 ) + Invested Capital (Q: Dec. 2024 ))/ count )
=-294.308 * ( 1 - 0% )/( (311.546 + 299.446)/ 2 )
=-294.308/305.496
=-96.34 %

where

Invested Capital(Q: Sep. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1247.212 - 41.968 - ( 893.698 - max(0, 99.886 - 1128.807+893.698))
=311.546

Invested Capital(Q: Dec. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1214.902 - 57.969 - ( 857.487 - max(0, 129.83 - 1104.285+857.487))
=299.446

Note: The Operating Income data used here is four times the quarterly (Dec. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Applied BioCode's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2024  Q: Dec. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-282.296/( ( (104.228 + max(152.114, 0)) + (98.787 + max(134.226, 0)) )/ 2 )
=-282.296/( ( 256.342 + 233.013 )/ 2 )
=-282.296/244.6775
=-115.37 %

where Working Capital is:

Working Capital(Q: Sep. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(31.774 + 192.516 + 10.819) - (41.968 + 0 + 41.027)
=152.114

Working Capital(Q: Dec. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(45.018 + 190.074 + 11.706) - (57.969 + 0 + 54.603)
=134.226

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Applied BioCode's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2024 )
=-259.354/1377.097
=-18.83 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Applied BioCode EBIT Related Terms

Thank you for viewing the detailed overview of Applied BioCode's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Applied BioCode Business Description

Traded in Other Exchanges
N/A
Address
12130 Mora Dr., Unit 2,, Santa Fe Springs, CA, USA, 90670
Applied BioCode Corp is engaged in designing, developing, manufacturing, and commercializing multiplex testing products for the in-vitro diagnostics market. The company's in-vitro diagnostic products focus on the molecular infectious disease segment of the market with assays that detect pathogens for gastrointestinal tract infections, respiratory infections, and sexually transmitted infections. The firm's products include barcoded magnetic bead technology (BMB). The BMB technology and detection systems assist in the development of multiplexed nucleic acids or protein detection assays. The company also develops applications for other areas of the diagnostics industry including life science research, agricultural testing, and veterinary markets.

Applied BioCode Headlines

No Headlines